Production, testing and perspectives of IPV and IPV combination vaccines: GSK biologicals' view

Biologicals

Volumn 34, Issue 2, 2006, Pages 163-166

  Duchêne, Michel ^a  

^a GSK   (Belgium)

Author keywords

Combined vaccines; IPV; Polio eradication; Production; Testing

Indexed keywords

POLIOMYELITIS VACCINE;

ARTICLE; DRUG COST; DRUG POTENCY; DRUG SCREENING; ERADICATION THERAPY; IN VIVO STUDY; PRIORITY JOURNAL; VACCINATION; VERO CELL; WORLD HEALTH ORGANIZATION;

POLIOVIRUS VACCINE, INACTIVATED; QUALITY CONTROL;

EID: 33646800523     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2006.03.010     Document Type: Article

References (12)

1. Lapinleimu K. Elimination of poliomyelitis in Finland. Rev Infectious Dis 6 2 (May-June 1984) 457-460
2. Van Wezel A.L., Van Steenis G., Van Der Marel P., and Osterhaus A.D.M.E. Inactivated Poliovirus vaccine: current production methods and new developments. Rev Infectious Dis 6 2 (May-June 1984) 335-340
3. Minor P.D., Schild G.C., Ferguson M., Mackay A., Magrath D.I., and John A. Genetic and antigenic variation in type 3 polioviruses: characterization of strains by monoclonal antibodies and T1 oligonucleotide mapping. J Gen Virol 61 (1982) 167-176
4. WHO Recommendations for the Production and Control of Poliomyelitis Vaccine (Inactivated), WHO TRS, n°910, 2002.
5. EP monograph: Poliomyelitis Vaccine (Inactivated) - 01/2005: 0214.
6. Ferguson M., Wood D.J., and Minor P.D. antigenic structure of poliovirus in inactivated vaccines. J Gen Virol 74 (1993) 685-690
7. EP.2.7.2.0 In vivo assay of poliomyelitis vaccine (inactivated): guideline on waiving of the in vivo assay of the poliomyelitis vaccine (inactivated) and its combinations - Pharmeuropa vol 17, n°2, April 2005.
8. Van Steenis G., Van Wezel A.L., and Sekhuis V.M. Potency testing of killed polio vaccine in rats. Dev Biol Basel, Kargen 47 (1981) 119-128
9. Vidor E., Meschievitz C., and Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J 16 (1997) 312-322
10. WHO/UNICEF Meeting - Geneva, 3rd June 2004. Informal consultation with manufacturers and regulators of polio vaccines.
11. Salk D. Herd effect and virus eradication with use of killed poliovirus vaccine. Dev Biol Dev Biol Stand Basel, Karger 47 (1981) 247-255
12. Salk J., Van Wezel A.L., Stockel P., Van Steenis G., Schumberger M., Meyran M., et al. Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis. Dev Biol Stand Basel, Karger 47 (1981) 181-198